Ikarian Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $102M | Sell |
800,000
-50,000
| -6% | -$6.24M | 8.3% | 1 |
|
|
2025
Q4 | $104M | Buy |
850,000
+100,000
| +13% | +$11.5M | 8.09% | 1 |
|
|
2025
Q3 | $75.2M | Buy |
+750,000
| New | +$67.6M | 7.59% | 2 |
|
|
2025
Q1 | – | Sell |
-750,000
| Closed | -$67.5M | – | 223 |
|
|
2024
Q4 | $67.5M | Buy |
750,000
+250,000
| +50% | +$24.2M | 9.19% | 1 |
|
|
2024
Q3 | $49.4M | Buy |
+500,000
| New | +$49.1M | 6.89% | 1 |
|
|
2024
Q2 | – | Sell |
-700,000
| Closed | -$66.4M | – | 156 |
|
|
2024
Q1 | $66.4M | Buy |
700,000
+150,000
| +27% | +$13.9M | 7.28% | 2 |
|
|
2023
Q4 | $49.1M | Buy |
550,000
+545,000
| +10,900% | +$40.5M | 4.6% | 3 |
|
|
2023
Q3 | $36.5M | Buy |
+5,000
| New | +$399K | 4.39% | 4 |
|
|
2023
Q2 | – | Sell |
-100,000
| Closed | -$7.62M | – | 158 |
|
|
2023
Q1 | $7.62M | Hold |
100,000
| – | – | 1.73% | 18 |
|
|
2022
Q4 | $8.3M | Sell |
100,000
-50,000
| -33% | -$4.05M | 2% | 14 |
|
|
2022
Q3 | $11.9M | Sell |
150,000
-200,000
| -57% | -$16.9M | 2.37% | 12 |
|
|
2022
Q2 | $26M | Buy |
+350,000
| New | +$26.3M | 4.74% | 2 |
|
|
2022
Q1 | – | Sell |
-542,400
| Closed | -$60.7M | – | 213 |
|
|
2021
Q4 | $60.7M | Sell |
542,400
-107,600
| -17% | -$13M | 9.05% | 1 |
|
|
2021
Q3 | $81.7M | Buy |
+650,000
| New | +$83.7M | 5.75% | 2 |
|
|
2021
Q2 | – | Sell |
-950,000
| Closed | -$129M | – | 293 |
|
|
2021
Q1 | $129M | Buy |
950,000
+41,900
| +5% | +$6.27M | 4.34% | 3 |
|
|
2020
Q4 | $128M | Buy |
908,100
+58,100
| +7% | +$7.44M | 5.64% | 3 |
|
|
2020
Q3 | $94.7M | Buy |
850,000
+600,000
| +240% | +$67.3M | 6.85% | 1 |
|
|
2020
Q2 | $28M | Hold |
250,000
| – | – | 2.23% | 6 |
|
|
2020
Q1 | $19.4M | Sell |
250,000
-100,000
| -29% | -$8.85M | 1.46% | 13 |
|
|
2019
Q4 | $33.3M | Buy |
+350,000
| New | +$30.3M | 5.39% | 2 |
|
Other funds holding XBI
